CBCRA
Canadian Breast Cancer Research Alliance
ACRCS
Alliance canadienne pour la recherche sur le cancer du sein
:
Search:
Advanced Search

A Novel Approach to Tumor Suppression with Microencapsulated Recombinant Cells

Show simple item record

dc.contributor.author Cirone, P.
dc.contributor.author Bourgeois, J. M.
dc.contributor.author Austin, R. C.
dc.contributor.author Chang, P. L.
dc.date.accessioned 2010-01-08T16:39:13Z
dc.date.available 2010-01-08T16:39:13Z
dc.date.issued 2002-07-01
dc.identifier.citation Cirone, P., Bourgeois, J.M., Austin, R.C. & Chang, P.L. A novel approach to tumor suppression with microencapsulated recombinant cells. Hum Gene Ther 13, 1157-66 (2002). en_US
dc.identifier.uri http://hdl.handle.net/1807.1/817
dc.description http://www.liebertpub.com en_US
dc.description Reproduced by generous permission of the publisher. en_US
dc.description.abstract A novel approach to cancer gene therapy is to implant microcapsules containing nonautologous cells engineered to secrete molecules with antineoplastic properties. The efficacy of this treatment is now tested in a mouse model bearing HER-2/neu–positive tumors. Nonautologous mouse myoblasts (C2C12) were genetically modified to secrete interleukin-2 linked to the Fv region of a humanized antibody with affinity to HER-2/neu. The resulting fusion protein, sFvIL-2, would encompass immune-stimulatory cytokine activity now targeted to the HER-2/neu–expressing tumor. These recombinant cells were then immunoprotected with alginate-poly- L-lysine-alginate microcapsules before implantation into tumor-bearing mice. Treatment with these encapsulated cells led to a delay in tumor progression and prolonged survival of the animals. The long-term efficacy was limited by an inflammatory reaction against the implanted microcapsules probably because of the secreted cytokine and antigenic response against the xenogeneic fusion protein itself. However, over the short term (initial 2 weeks), efficacy was confirmed when a significant amount of biologically active interleukin-2 was detected systemically, and targeting of the fusion protein to the HER-2/neu–expressing tumor was shown immunohistochemically. The tumor suppression in the treated animals was associated with increased apoptosis and necrosis in the tumor tissue, thus demonstrating successful targeting of the antiproliferative effect to the tumors by this delivery paradigm. In conclusion, this new approach to systemic cancer gene therapy needs to be modified to provide long-term delivery, but has demonstrated short-term efficacy and potential to become a cost-effective, benign, and non-viral–based adjunct to the current armory of anticancer strategies. en_US
dc.description.provenance Submitted by Kelly Lee (klee@cbcra.ca) on 2010-01-08T16:39:13Z No. of bitstreams: 1 Chang_2002.pdf: 478250 bytes, checksum: c38ffdbe02807e985335205c1551a67c (MD5) en
dc.description.provenance Made available in DSpace on 2010-01-08T16:39:13Z (GMT). No. of bitstreams: 1 Chang_2002.pdf: 478250 bytes, checksum: c38ffdbe02807e985335205c1551a67c (MD5) Previous issue date: 2002-07-01 en
dc.language.iso en en_US
dc.publisher Mary Ann Liebert, Inc. en_US
dc.title A Novel Approach to Tumor Suppression with Microencapsulated Recombinant Cells en_US
dc.type Article en_US

Files in this item

Files Size Description Format View
Chang_2002.pdf 478.2Kb PDF View/Open

This item appears in the following category

Show simple item record

Browse

Tools